Changes in type VI collagen degradation reflect clinical response to treatment in rheumatoid arthritis patients treated with tocilizumab.
Christian S ThudiumPeder FrederiksenMorten A KarsdalAnne-Christine Bay-JensenPublished in: Arthritis research & therapy (2024)
These findings suggest that quantifying type VI collagen turnover may aid in identifying patients less likely to respond to treatment, indicating a new path towards optimizing patient care. Further studies are needed to validate these findings and explore the underlying mechanisms driving the observed relationships.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- combination therapy
- bone mineral density
- body composition
- juvenile idiopathic arthritis
- patient reported outcomes
- systemic sclerosis
- replacement therapy
- systemic lupus erythematosus
- idiopathic pulmonary fibrosis